Children with Fragile X syndrome (FXS) share some traits with those with autism spectrum disorder (ASD), but exhibit several differences…
Steve Bryson, PhD
Steve holds a PhD in biochemistry from the Faculty of Medicine at the University of Toronto, Canada. As a medical scientist for 18 years, he worked in both academia and industry, where his research focused on the discovery of new vaccines and medicines to treat inflammatory disorders and infectious diseases. Steve is a published author in multiple peer-reviewed scientific journals and a patented inventor.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Articles by Steve Bryson, PhD
Researchers in Kansas and California will investigate people with the FMR1 premutation who are at risk of developing fragile X-associated…
Tetra Therapeutics has amended the protocols of two ongoing late-stage clinical trials testing zatolmilast, its experimental oral therapy for…
How the brain processes sound varies across three neuropsychiatric feature-based subgroups of women who carry so-called premutations in FMR1, the…
A deficiency in the FMRP protein, the underlying cause of fragile X syndrome (FXS), may affect the system within…
The NIH Toolbox Cognition Battery (NIHTB-CB) test accurately detects developmental changes in cognitive function among young people with intellectual…
An enzyme called matrix metalloproteinase 9 (MMP-9) is found at higher levels in the blood of people with fragile…
The International Fragile X Premutation Registry (IFXPR) — now enrolling — aims to accelerate research to better understand the…
A combination of approved medicines — lovastatin and minocycline — significantly improved several behavioral characteristics in adults with fragile…
Boys, ages 2 to 6, with fragile X syndrome who have trouble talking can join the BRIDGE study to…